Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Benralizumab, an Interleukin-5 Receptor-α Monoclonal Antibody as Treatment of Acute Exacerbations of Airways Disease

NCT04098718 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT04098718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04098718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Benralizumab, an Interleukin-5 Receptor-α Monoclonal Antibody as Treatment of Acute Exacerbations of Airways Disease
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Unknown status
Start date
March 29, 2021
Completion date
November 19, 2024
Enrollment
158 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, copd